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Abstract
The problem addressed here is that of simultaneous treatment of several gene expression datasets, possibly
collected under different experimental conditions and/or platforms. Using robust statistics, a large scale statistical
analysis has been conducted over 20 datasets downloaded from the Gene Expression Omnibus repository. The
differences between datasets are compared to the variability inside a given dataset. Evidence that meaningful
biological information can be extracted by merging different sources is provided.
Background
Many genomewide expression datasets have been published during the past ten years. Repositories, such
as the Gene Expression Omnibus (GEO) database [1], have made available an impressive wealth of data.
Using them as a whole, instead of restricting statistical studies to one particular dataset, is tantalizing. Two
recently published R/Bioconductor packages [2, 3] provide various tools for merging datasets coming from
different studies. However, a serious doubt has been cast by Haibe-Kains et al. [4], after comparing two large
scale pharmacogenomic studies: whereas both studies had a good overall correlation, important discordances
could be observed. Thus, the following crucial question remains to be answered: is it statistically legitimate
to merge datasets coming from different studies? An attempt at answering this question is reported here.
Merging different datasets, requires prior checking that the information they contain is compatible,
and hence that detected differences between gene expressions under different conditions are not artifacts,
due to experimental or data processing methods. An obvious obstacle to simultaneous treatment is that
expression data collected under different experimental conditions and/or platforms usually have incompatible
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distributions, which differ sometimes by several orders of magnitude [5,6]. A solution is provided by robust (or
distribution-free) statistics [7,8]. Robust methods amount to replacing actual values by ranks, or equivalently
by empirical distribution functions or van der Waerden’s normal scores [7, p. 309]. This idea has already
been applied to expression data in several papers, including [9–11]. However, to the best of our knowledge, a
large scale analysis assessing the reproducibility of information from one dataset to another, is still missing.
We have conducted such an analysis over 20 GEO datasets, totalling 17 745 genomewide expression samples.
For the data treatments presented here, the statistical language R [12] has been used. Our set of functions,
together with a manual, has been made available online as supplementary information. Throughout the
article, we consider data matrices (also called assay data in [13]) as containing expression data relative to
a set of genes. Each row corresponds to a different gene symbol, or feature, each column to a different
data vector or sample (see Table 2 in [1]). Such a matrix is deduced from raw datasets, available on the
GEO repository, though standard treatments: annotation and reduction [14]. Several R packages [15, 16]
that perform these operations and output data matrices such as considered here, are available. We have
encoded our own functions. We have chosen a data structure in which each data matrix is paired with its
information matrix. The columns of the information matrix are labelled by the same numbers as the paired
data matrix. Its rows contain the different information fields of the data. Our focus here is on overexpression
or underexpression of genes, in different tissues or cancer types.
Our objective was twofold. On the one hand, we wanted to check whether the information on genes,
contained in different data matrices, was compatible, and to which extent. This was done on a set of 20
different matrices. Various statistical treatments were performed. The first one consisted in computing
correlations between median columns of the matrices. Vectors of pairwise correlations between rows were
also compared. Then multivariate analysis over assays of gene symbols was applied: Wilcoxon and Kruskal-
Wallis tests, factor and principal component analysis (PCA). The results were compared to those obtained
by sorting a single matrix according to different keywords. All comparisons showed not perfect, but highly
significant correlations. However, it was also found that in all cases, a sizeable proportion of symbols were
good discriminators of the different matrices. But this was also found to hold between two submatrices
inside a given dataset. Therefore, it cannot be regarded as an obstacle to merging different datasets. On the
other hand, we wanted to know whether biological information could be consistently retrieved from matrices
collated from different sources. Two merged sets of matrices were made. The first one came from general
cancer cell datasets, from which samples of breast and lung tumors were extracted. The second one was
made of blood RNA datasets, coming from healthy individuals, or from leukemias. In both cases, evidence
that already known biological information could be extracted from merged matrices was found.
Methods
The datasets available from the GEO repository [1], collate sets of expression vectors, or samples. Several
R/Bioconductor packages can be used to download and format the data [15,16]. We have chosen to encode
in R our own functions. Our R script has been made available online, together with a user manual. Our
formatting choices are described below.
In a GEO dataset two types of information are available for each sample. The first type consists of
numeric values corresponding to a set of probes. The second type are character-type informations on the
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experimental setting. We have chosen to separate the two types into data matrices and information matrices.
In the data matrix, probes are associated to gene symbols with the use of different Bioconductor annotation
packages according to the platform [17–20]. After annotation, some symbols are duplicated. Several methods
can be used to eliminate duplicates. We have chosen to keep the row with the largest interquartile range, as
in [14], because we believe that this is the most statistically coherent choice. After annotation and reduction,
the data matrix, with gene symbols as row names, and series numbers as column names, is saved as a single
R object for future use. The information matrix has the same column names as the corresponding data
matrix. Its rows correspond to the different fields.
Our merging function reduces data matrices to common row names. For information matrices, differ-
ent sets of data usually have different information fields. This was taken into account when merging two
information matrices, by indexing the rows of the merged matrix by the union of row names in the initial
information matrices.
Two R/Bioconductor packages have recently been issued for merging GEO datasets [2, 3]. In [2], quan-
tile discretization, normal discretization normalization, gene quantile normalization, median rank scores,
quantile normalization (QN) are proposed. In [2,3], the Batch Mean-Centering method, Distance-Weighted
Discrimination, Z-score standardization, and the Cross-Platform Normalization method are proposed. An
Empirical Bayes (EB) method is available in both packages. For the results reported here, only classical
methods were used, and we consider them as sufficient to establish our main points, our focus being on
overexpression or underexpression of genes, in different tissues or cancer types.
As in [9–11], we have made the choice to use robust statistics [7, 8]. This implies changing the columns
of a data matrix into distribution free values. The usually proposed transformation replaces the i-th value
xi by its rank Ri if xi is the Ri-th smallest value in the column. However, ranks range between 1 and the
number of rows. The problem is that different matrices may have different numbers of rows (gene symbols).
In order to get a unique range of values for all matrices, it seems preferable to use a scale free score. The
simplest such score is the Empirical Cumulative Distribution Function (ECDF): its value at xi is Ri/n, if n
is the number of rows. Graphical displays look more familiar if another score is used: the van der Waerden’s
normal score [7, p. 309]. It consist of replacing xi by φ(Ri/(n+ 1)), where φ is the quantile function of the
standard normal distribution. With the ECDF, the distribution of each column becomes uniform on the
interval [0, 1], whereas with the normal score it becomes standard normal. Results reported above have been
obtained with the normal score, but they are not essentially different if the ECDF is used instead.
In statistical inference, the choice of robust statistics must be made coherent. This is the reason why we
have replaced the usual normal-sample techniques by their robust equivalent, and used medians instead of
means, Spearman’s correlation instead of Pearson’s [7, p. 422-431], Wilcoxon (or Mann-Whitney) location
test instead of Student’s t-test [7, p. 268-278], Kruskal-Wallis test instead of one-way analysis of variance [7,
p. 363-372]. When comparing several matrices to detect location diffferences, the Kruskal-Wallis test was run
over all common rows. When differentiating overexpression from underexpression, a one-sided Wilcoxon test
was run. The same test being used for a large number of features, a False Detection Rate (FDR) correction
of p-values by the Benjamini-Yekutieli method [21] was systematically applied. Features were ranked from
most to least significant, either by sorting p-values in increasing order, or by sorting the values of the test
statistic instead. We considered as significant, any feature with a (FDR-corrected) p-value smaller than 5%.
Once a set of (significant) features had been selected, the corresponding rows were concatenated into single
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vectors. These vectors were taken as variables, and the samples as individuals, for a PCA. Figures 3 to 5
were obtained by projecting the samples as points onto the first principal plane, and differentiating their
initial data matrices by colors. Precise R commands can be found in the user manual made available online.
Results
The 20 datasets that were downloaded from the GEO repository are detailed in Table 1. They were selected
on a criterion of size (number of samples: 500 or more). The 20 matrices together amount to 17 745 samples.
To each study, a three-letter acronym was attached; these acronyms will be used in what follows.
acronym reference series number platform number symbols (rows) samples (columns)
EPO [22] 2109 570 20 184 2158
PMM [23] 2658 570 20 184 559
AML [24] 6891 570 20 184 537
HBI [25] 7307 570 20 184 677
MIL [26] 13159 570 20 184 2 096
MDS [27] 15061 570 20 184 870
PLE [28] 20142 6947 19 626 1 240
MMD [29] 24080 570 20 184 559
DLB [30] 31312 570 20 184 498
PRS [31] 33828 10558 20 768 881
CCL [32] 36133 15308 18 722 917
BEC [33] 36192 6947 19 628 911
WBS [34] 36382 6947 19 628 991
GSC [35] 36809 570 18 260 812
MBI [36] 37069 570 18 260 590
CCC [37] 39582 570 20 184 566
PVA [38] 48152 6947 19 628 705
HPS [39] 48348 6947 19 628 734
XMD [40] 48433 570 20 184 823
HAV [41] 48762 6947 19 628 621
Table 1: Twenty GEO series have been chosen, coming from four different platforms. To each of them a three
letters acronym was associated. The table gives the acronym, a recent reference, the GEO series number,
the platform number. For the data matrix (or assayData), the number of symbols after annotation and
reduction, and the number of columns (samples) are given. All 20 data matrices had 15 562 gene symbols in
common.
In the results reported here, each data matrix has been transformed by replacing its column values, by
the corresponding van der Waerden normal scores [7, p. 309]. Similar results were obtained when replacing
column values by their empirical distribution function (see methods section).
The first treatment that was applied consisted in computing, for each dataset, the median of all rows,
reduced to the 15 562 common gene symbols. This gave 20 vectors of length 15 562, the correlation matrix
of which is given in Table 2. A positive (negative) correlation between vectors of size 15 562 is significant at
threshold 5% if it is larger than 0.013 (smaller than −0.013); thus all correlations of Table 2 can be regarded
as significant.
Figure 1 shows a factor analysis of the 20 variables. Fifteen of them can be clustered into four groups.
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EPO PMM AML HBI MIL MDS PLE MMD DLB PRS
EPO 1.00 0.80 0.71 0.92 0.63 0.82 0.55 0.48 0.59 0.18
PMM 0.80 1.00 0.75 0.79 0.63 0.81 0.56 0.63 0.55 0.19
AML 0.71 0.75 1.00 0.68 0.76 0.85 0.61 0.58 0.59 0.18
HBI 0.92 0.79 0.68 1.00 0.58 0.76 0.53 0.46 0.53 0.18
MIL 0.63 0.63 0.76 0.58 1.00 0.78 0.58 0.67 0.61 0.14
MDS 0.82 0.81 0.85 0.76 0.78 1.00 0.69 0.52 0.60 0.18
PLE 0.55 0.56 0.61 0.53 0.58 0.69 1.00 0.40 0.45 0.22
MMD 0.48 0.63 0.58 0.46 0.67 0.52 0.40 1.00 0.50 0.11
DLB 0.59 0.55 0.59 0.53 0.61 0.60 0.45 0.50 1.00 0.12
PRS 0.18 0.19 0.18 0.18 0.14 0.18 0.22 0.11 0.12 1.00
CCL 0.81 0.74 0.69 0.75 0.65 0.77 0.55 0.54 0.56 0.20
BEC 0.56 0.49 0.43 0.65 0.38 0.48 0.63 0.32 0.35 0.21
WBS 0.57 0.58 0.62 0.54 0.58 0.70 0.94 0.40 0.46 0.23
GSC 0.59 0.61 0.69 0.57 0.63 0.74 0.66 0.46 0.49 0.15
MBI 0.60 0.63 0.70 0.58 0.65 0.75 0.64 0.48 0.50 0.15
CCC 0.77 0.62 0.64 0.67 0.59 0.67 0.50 0.49 0.53 0.15
PVA −0.09 −0.10 −0.13 −0.09 −0.14 −0.16 −0.30 −0.09 −0.09 0.16
HPS 0.62 0.62 0.66 0.58 0.62 0.74 0.93 0.43 0.49 0.24
XMD 0.90 0.81 0.72 0.84 0.65 0.83 0.56 0.51 0.56 0.19
HAV 0.60 0.60 0.64 0.56 0.61 0.73 0.89 0.42 0.48 0.21
CCL BEC WBS GSC MBI CCC PVA HPS XMD HAV
EPO 0.81 0.56 0.57 0.59 0.60 0.77 −0.09 0.62 0.90 0.60
PMM 0.74 0.49 0.58 0.61 0.63 0.62 −0.10 0.62 0.81 0.60
AML 0.69 0.43 0.62 0.69 0.70 0.64 −0.13 0.66 0.72 0.64
HBI 0.75 0.65 0.54 0.57 0.58 0.67 −0.09 0.58 0.84 0.56
MIL 0.65 0.38 0.58 0.63 0.65 0.59 −0.14 0.62 0.65 0.61
MDS 0.77 0.48 0.70 0.74 0.75 0.67 −0.16 0.74 0.83 0.73
PLE 0.55 0.63 0.94 0.66 0.64 0.50 −0.30 0.93 0.56 0.89
MMD 0.54 0.32 0.40 0.46 0.48 0.49 −0.09 0.43 0.51 0.42
DLB 0.56 0.35 0.46 0.49 0.50 0.53 −0.09 0.49 0.56 0.48
PRS 0.20 0.21 0.23 0.15 0.15 0.15 0.16 0.24 0.19 0.21
CCL 1.00 0.56 0.56 0.56 0.59 0.74 −0.08 0.61 0.92 0.60
BEC 0.56 1.00 0.64 0.37 0.37 0.45 −0.13 0.65 0.57 0.59
WBS 0.56 0.64 1.00 0.64 0.63 0.49 −0.29 0.95 0.57 0.88
GSC 0.56 0.37 0.64 1.00 0.94 0.61 −0.19 0.66 0.57 0.64
MBI 0.59 0.37 0.63 0.94 1.00 0.62 −0.17 0.66 0.59 0.64
CCC 0.74 0.45 0.49 0.61 0.62 1.00 −0.09 0.53 0.75 0.51
PVA −0.08 −0.13 −0.29 −0.19 −0.17 −0.09 1.00 −0.27 −0.08 −0.26
HPS 0.61 0.65 0.95 0.66 0.66 0.53 −0.27 1.00 0.62 0.90
XMD 0.92 0.57 0.57 0.57 0.59 0.75 −0.08 0.62 1.00 0.60
HAV 0.60 0.59 0.88 0.64 0.64 0.51 −0.26 0.90 0.60 1.00
Table 2: For each of the 20 data matrices of Table 1, the median column value of each gene symbol was
computed. This gave 20 vectors with length 15 562 (number of common symbols). The table gives pairwise
correlations between the 20 vectors.
• PMM, EPO, XMD, HBI, CCL, CCC. Among these six datasets, four are generalist studies involving
different tissues and conditions (EPO, HBI, XMD, CCL); CCC concerns colon cancer, and PMM
multiple myelomas. Observe that CCL, which was obtained under a platform different from the five
others, has excellent correlations with them (between 0.74 and 0.92).
• WBS, PLE, HPS, HAV. All four correspond to blood RNA samples from healthy patients.
• MIL, AML, MDS. All three correspond to leukemias.
• GSC, MBI. These two matrices correspond to similar tissues (blood samples), and similar conditions
(critical injuries and burn injuries). Moreover, they were produced on the same platform, by the same
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Figure 1: Factor analysis of median columns for 20 datasets. The 20 variables are projected onto the first
principal plane of the PCA. Four clusters are identified.
organization. Their excellent correlation (0.94) is not a surprise.
Three datasets, BEC, DLB, MMD have relatively good correlations with those of the above four groups
(around 0.5), but no particular links with those groups, nor between themselves. The relative surprise comes
from the weak correlations of PRS, and the negative correlations of PVA. Both come from blood RNA
samples, and they could have been expected to be close to the WBS, PLE, HPS, HAV group. That PRS
and PVA are far from any other matrix, can be explained by their inner heterogeneity. It is illustrated for
PVA on Figure 2, where the values over features ALPP and CA4 are represented: samples separate into 4
clusters, according to over- or underexpression of the two genes. As an example, if PVA is split into samples
for which the value of ALPP is positive (overexpression), or negative (underexpression), and the row medians
are calculated over the two submatrices as before, a correlation of −0.69 is found: thus one half of PVA has
a strong negative correlation with the other half. Similar results are obtained for many other features. We
considered that the heterogeneity of PVA and PRS did not qualify them for merging.
For each matrix, we also computed all possible pairwise row correlations: 20 vectors of more than 121
millions of pair-correlations were obtained: this is the technique used to evaluate genes for cross-platform
consistency of expression patterns in [42]. As expected, the correlation matrix had smaller values than that of
Table 2. For instance, the correlation of CCL with XMD was 0.53 instead of 0.92, but still highly significant
because of the large number of values.
Correlations between column medians or pair-correlations, is too crude a criterion to judge the homo-
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Figure 2: Values of PVA on CA4 versus ALPP. Samples separate into 4 clusters, according to over- or
underexpression of the two genes.
geneity of two datasets. As an example, GSC and MBI have an excellent median correlation of 0.94, and
several good reasons to be similar. Yet, when each feature is tested for significant differences by the Kruskal-
Wallis test, 14 800 significant features out of 18 260 are detected (see methods section for details). The same
occurred for any pair of datasets: the distributions of rows had significantly different location parameters,
for a majority of features. This means that, for a majority of genes, the ranks of their expressions in the
first dataset are significantly smaller or larger than in the second.
Since discrepancies appear to be observed between any two datasets, it must be decided whether they are
due to actual biological information, or to a statistical artifact, induced by the experimental setting or the
platform. For this, we focused on the dataset MIL (GSE13159 [26]), that has 2 096 samples. The samples
were sorted into six submatrices, according to six keywords: Healthy (74 samples), ALL (acute lymphoblastic
leukemia, 750 samples), AML (acute myeloid leukemia, 542 samples), CLL (chronic lymphocytic leukemia,
448 samples), CML (chronic myelogenous leukemia, 750 samples), MDS (myelodysplastic syndrome, 202
samples). Then the same treatments as before were applied. Firstly the six median columns were computed,
and their correlation matrix was obtained (Table 3).
The values are between 0.85 and 0.99, which is in the range of the best correlations of Table 2. As a control,
we made a partition of the same matrix into 6 random subsets, with the same numbers of samples as above,
and computed the correlation matrix in the same way. On the control random partition, all correlations
were above 0.997. This proves that the partition into keywords does contain meaningful differences. Indeed,
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Healthy ALL AML CLL CML MDS
Healthy 1.00 0.92 0.96 0.86 0.98 0.99
ALL 0.92 1.00 0.95 0.91 0.90 0.91
AML 0.96 0.95 1.00 0.89 0.96 0.97
CLL 0.86 0.91 0.89 1.00 0.84 0.85
CML 0.98 0.90 0.96 0.84 1.00 0.98
MDS 0.99 0.91 0.97 0.85 0.98 1.00
Table 3: The data matrix MIL was partitioned according to the 6 keywords Healthy, ALL, AML, CLL,
CML, MDS. For each of the six submatrices, the median column of each feature was computed. This gave
6 vectors with length 20 184 (number of symbols in MIL). The table gives the correlations of the 6 vectors.
these differences were detected by the Kruskal-Wallis test: out of the 20 184 features, 18 301 were found
significant. Twenty-two features had Kruskal-Wallis p-value below 10−300: SOX4, SYNGR2, ERLIN1, FAH,
C7orf23, PSMA6, RTN3, UHRF1, ADAM28, BLK, FUCA2, CD79A, ADA, MYL6B, HEBP1, LEF1-AS1,
LEF1, AFF3, COL9A2, MICALL2, MPO, PPM1K. A PCA of the corresponding rows of MIL was run, and
the samples projected as points onto the first principal plane, differentiating submatrices by colors (Figure
3). The two submatrices ALL (blue points) and CLL (brown points) are clearly separated from the rest.
Differences inside a given dataset can be induced by several factors. Two factors may not induce differ-
ences of the same order of magnitude. However, there is no statistical reason why a dataset like MIL should
not be used as a whole, and many ways to verify that the observed differences correspond to actual biological
information. Here is an example. Stirewalt et al. [43] list a group of 7 genes displaying increased expression in
acute myeloid leukemia samples: BIK, CCNA1, FUT4, IL3RA, HOMER3, JAG1, WT1. When a one-sided
Wilcoxon test is applied to the submatrix AML versus the rest of MIL, those 7 genes are among the most
significant: their p-values range between 6.7 × 10−130 and 4.3 × 10−42. The most significant, HOMER3,
ranks 54-th among the 20 184 features of MIL.
If observed differences between two datasets (like GSC and MBI) are of the same order of magnitude as
differences inside a given dataset, such as caused by a significant factor (see figure 3), it can be admitted as
statistically legitimate to merge the two datasets. That meaningful information can be obtained from the
merging, remains to be proved. In the following experiments, matrices to be merged were selected in the
clusters detected by factor analysis (Figure 1).
Our first experiment consisted in extracting samples corresponding to breast and lung tumors, from the
three matrices CCL, EPO, and XMD. CCL has 56 samples of breast tumors, and 166 of lung tumors, EPO
has 367 and 143, XMD has 32 and 152. Two matrices “Breast” and “Lung” were made by merging the six
submatrices three by three, according to tissues. They had 18 466 features in common, by 455 samples for
Breast, and 461 for Lung.
The Kruskal-Wallis test was run on the six separated submatrices, then on the two matrices Breast
and Lung. The ten most significant symbols were extracted, and a PCA was run as before. The results
are displayed on Figure 4. Significant symbols when the 6 matrices are separated (left panel) are different
from significant symbols separating Breast and Lung (right panel). On the left panel, it is clear that the
information on the dataset (CCL, EPO, or XMD) dominates the separation Breast vs. Lung: samples
coming from CCL are on the left, from EPO on the right, from CCL in the middle. But on the right panel,
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Figure 3: Dataset MIL, partitioned into 6 submatrices according to keywords Healthy, ALL, AML, CLL,
CML, MDS. PCA of the 22 symbols with Kruskal-Wallis p-value under 10−300: SOX4, SYNGR2, ER-
LIN1, FAH, C7orf23, PSMA6, RTN3, UHRF1, ADAM28, BLK, FUCA2, CD79A, ADA, MYL6B, HEBP1,
LEF1-AS1, LEF1, AFF3, COL9A2, MICALL2, MPO, PPM1K. Samples are represented by points, with six
different colors.
the two types of tumors are also clearly separated. Separators include GATA3 on the right side (Breast),
IGF2BP3 on the left side (Lung). Two articles, among others, show the importance of GATA3 for breast
cancer [44, 45]. In [46], the link of IGF2BP3 to lung cancer is explicitly stated.
Further information was obtained by running a one-sided Wilcoxon test to detect symbols separating
both types of tumor. Then the Molecular Signature database C2 [47] was searched for symbols matching
them. Among the 20 genes found most significantly overexpressed in breast tumors by our test, 11 were
inside genesets of C2 relative to breast cancers, and outside all genesets relative to lung tumors: EFHD1,
IRX5, MUCL1, PRLR, PTGER3, RGL2, TRIL, TRPS1, VAV3, WWP1, ZG16B. Seven of these genes can
be found in the G2SBC database [48] and for 10 out of 11, we have found at least one reference relating
it to breast cancer. Conversely, among the most significant genes for lung tumor, the following were found
in C2 genesets related to lung and not in those related to breast: ALDH3B1, DARS, PRPSAP2, FAM96B,
MBIP, LRRC20. The overexpression of ALDH3B1 in lung tumors has been reported in [49]. Santarius et
al. [50] gives lists of genes, the overexpression of which is associated to different types of human cancers.
The genes detected as significantly overexpressed in Breast by our test, that were also among class III genes
related to breast cancer in Table 1 of [50], were FGFR1, BAG4, MDM2, YWHAB, ZNF217. For Lung, they
were EGFR, MET, YWHAZ, MYC, NKX2-1, DCUN1D1. These findings would require further confirmation
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Figure 4: Principal component analysis of two assays of 10 symbols in 6 submatrices, extracted from CCL,
EPO, and XMD according to keywords “Breast” and “Lung”. The six submatrices are separated on the
right panel, they have been merged on the right panel. In each case the 10 most significant features for the
Kruskal-Wallis test are taken as variables. The two sets of 10 symbols are disjoint. Samples are represented
by red points (Breast) or blue points (Lung).
over larger datasets. Yet they provide evidence that meaningful biological information can be extracted by
merging generalist matrices such as CCL, EPO and XMD.
Our next experiment consisted in merging the two groups of blood RNA datasets, found to be homoge-
neous on the correlation analysis (Figure 1): HAV, HPS, PLE, WBS for healthy individuals, AML, MDS,
for leukemias. The samples of MIL were separated into MILh (Healthy), and MILl (leukemias). The left
panel of Figure 3 shows the first plane of the PCA for the same 22 features as in Figure 2, the 8 matrices
being represented by different colors. It turns out that the samples corresponding to MILh are mixed on
the representation with the other MIL points. Thus they were removed from the matrix “Healthy”, whereas
“Leukemia” was made by merging AML, MDS, and MILl. The Kruskal-Wallis test between Healthy and
Leukemia, detected 16 977 significant features out of 17 691, among which 7 970 had a null p-value. The
right panel of Figure 5 shows the PCA over 10 of them.
The one-sided Wilcoxon test was run to detect which symbols were significantly overexpressed in
leukemias. For that test, a set of 4 191 symbols had a null p-value. A second set of symbol was extracted from
C2: those appearing in leukemia-related genesets. The C2 set has 5 688 symbols, and the intersection with
the first contains 1 617, which is highly significant for Fisher’s hypergeometric test (P = 1.36× 10−51). The
ten symbols found most significant for leukemia by the Wilcoxon test were RPL34, GABARAP, RPL36A,
H2AFV, CSDE1, DNTTIP2, OPHN1, PABPC3, PNRC1, RPSA. Among those 10, 8 appeared in the
leukemia-related genesets of C2. The symbol H2AFV is found in six of them. Another noteworthy re-
sult concerns the pair of genes NUP98-TOP1, shown to be related with leukemia in [51]. When genes are
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Figure 5: On the left panel, PCA of HAV, HPS, PLE, WBS, MILh (Healthy = red points), and AML, MDS,
MILl (Leukemia = blue points), for the same 22 features as in Figure 2. On the right panel, HAV, HPS, ML,
WBS, have been grouped into Healthy, AML, MDS, MILl into Leukemia. The assay is made of 10 random
features among the 7 970 having a null Kruskal-Wallis p-value.
ranked by decreasing order of significance, NUP98 and TOP1 have ranks 187 and 65 respectively, which
confirms their link with leukemia.
Another experiment was run on the same matrices, by separating acute myeloid leukemia samples, from
all other samples. Thus the same calculations that had been run inside MIL before, were repeated over
a larger number of samples. The acute myeloid leukemia samples were taken from AML and MIL (1 076
samples), others were obtained by merging HAV, HPS, PLE, WBS, MDS, with the non-AML samples of
MIL (6 010 samples). The one-sided Wilcoxon test of comparison was run. For the 7 genes signaled as
overexpressed in AML by [43], the results were much more significant as before: the least significant p-
value was that of BIK: 8.4 × 10−35, whereas FUT4 and HOMER3 had p-values below machine precision.
Contrarily to the study that had been conducted inside MIL, a clear confirmation was also obtained for the
genes reported by [43] to be underexpressed in case of AML. Five of them were in the common features of
our matrices, four had p-values smaller than 10−100 for underexpression in AML. In particular, PELO and
PLXNC1 who had not been found significantly underexpressed in the first experiment, now had p-values
3.5× 10−238 and 4.4× 10−168 in the test on merged matrices.
Discussion
A new set of R functions has been developed. Like other packages [15,16], it performs the usual formatting
operations. It also offers new functionalities for sorting lists of datasets according to information keywords.
Various robust statistics techniques are encoded. The script and a user manual have been made available
online. Using these R functions, a large scale study of 20 GEO datasets, totalling 17 745 samples, has been
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conducted.
Our first conclusion is that Haibe-Kains et al. [4] were right in observing that inconsistencies between
datasets make it dangerous to merge them without precautions. The risk is to declare as biologically
significant, observations which are actually statistical artifacts. The first precaution is to transform the data
into distribution-free values, i.e. to use robust statistics. This implies replacing the data of each sample
by their empirical distribution function, or some other distribution-free score [7, 8]. Even after data have
been homogenized, important discrepancies remain. For this reason, checking comparability between studies
before merging them is imperative. One possible measure of similarity (among others, see for instance [42]) for
two datasets is the correlation between medians, which has been used here. Two sets of samples corresponding
to different conditions inside one given homogeneous dataset usually have correlations of medians above 0.8
(see Table 3). Arguably, it can be considered that two different datasets can safely be merged, if all paired-
correlations between medians are above 0.8. This is not always the case, even between datasets coming
from the same tissues, obtained under the same platform (see Table 2). Further ways of investigating
possible discrepancies involve multivariate statistics. Graphical methods include Factor Analysis, Principal
Component Analysis, Discriminant Analysis [52]. Inference can be done using the robust equivalents of usual
normal-sample methods, i.e. Wilcoxon test instead of Student’s t-test, Kruskal-Wallis instead of one-way
anova, etc. When repeatedly applying such a test to a set of symbols, a False Detection Rate (FDR) correction
must be applied to the p-values. We have chosen the Benjamini-Yekutieli method [21]. Our observation was
that, even after FDR correction, the tests usually detect a sizeable proportion of all symbols as significant
for discrimination, either between several different datasets, or between different types of samples within the
same dataset. We believe that relevant biological information can be obtained from applying a discriminating
test, then ranking features according to their degree of significance, i.e. ordering the values obtained over
each feature by the test statistic. In the cases considered here (breast tumors against lung tumors, healthy
blood samples against leukemias, acute myeloid leukemia against other blood RNA samples), it was observed
that among the most significant symbols, a large proportion of them were already known as being related
to the corresponding cancers. This can be viewed as evidence that meaningful biological information can be
extracted by merging different datasets. We believe that important new findings could be obtained by the
same method, being aware that a statistical listing of significant symbols does not necessarily imply that all
listed symbols correspond to true biological information. Such a list must necessarily be expert-curated for
biochemical validation.
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Additional material has been provided as a compressed directory available online:
http://ljk.imag.fr/membres/Bernard.Ycart/publis/sagd.tgz
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References
1. Edgar R, Domrachev M, Lash AE:Gene Expression Omnibus: NCBI gene expression and hybridization
array data repository. Nucleic Acids Research 2002, 30:207–210.
2. Heider A, Alt R: virtualArray: a R/bioconductor package to merge raw data from different microar-
ray platforms. BMC Bioinformatics 2013, 14:75. [R package version 1.8.0].
3. Taminau J: inSilicoMerging: Collection of Merging Techniques for Gene Expression Data 2014,
[http://insilicodb.com/]. [R package version 1.8.0].
4. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, Quackenbush J: Inconsistency in
large pharmacogenomic studies. Nature 2013, 504.
5. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS:Analysis of matched mRNA measurements
from two different microarray technologies. Bioinformatics 2002, 18:405–412.
6. Mah N, Thelin A, Lu T, Nikolaus S, Kuhbacher T, Gurbuz Y, Eickhoff H, Kloppel G, Lehrach H, Mellgard
B, Costello CM, Schreiber S: A comparison of oligonucleotide and cDNA-based microarray systems.
Physiol Genomics 2004, 16:361–370.
7. Gibbons JD, Chakraborti S: Nonparametric statistical inference. Dekker, Basel, 4th edition 2003.
8. He´ritier S, Cantoni E, Copt S, Victoria-Cantoni MP: Robust methods in biostatistics. Wiley, New York 2009.
9. Tsodikov A, Szabo A, Jones D: Adjustments and measures of differential expression for microarray
data. Bioinformatics 2002, 18:251–260.
10. Warnat P, Eils R, Brors B:Cross-platform analysis of cancer microarray data improves gene expression
based classification of phenotypes. BMC Bioinformatics 2005, 6:265.
11. Breitling R, Armengaud P, Amtmann A, Herzyk P:Rank products: a simple, yet powerful, new method to
detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004, 573:83–
92.
12. R Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Com-
puting, Vienna, Austria 2013, [http://www.R-project.org/]. [ISBN 3-900051-07-0].
13. Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik
K, THothorn, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini A, Sawitzki G, Smith C, Smyth
G, Tierney L, Yang J, Zhang J: Bioconductor: open software development for computational biology
and bioinformatics. Genome Biol. 2004, 5.
14. Gentleman R, Carey V, Huber W, Hahne F: genefilter: genefilter: methods for filtering genes from microarray
experiments. [R package version 1.46.1].
15. Davis S, Meltzer P: GEOquery: a bridge between the Gene Expression Omnibus (GEO) and Bio-
Conductor. Bioinformatics 2007, 14:1846–1847.
16. Taminau J: inSilicoDb: Access to the InSilico Database 2011, [https://insilicodb.org]. [R package version 1.7.4].
17. Carlson M: hgu133plus2.db: Affymetrix Human Genome U133 Plus 2.0 Array annotation data(chip hgu133plus2).
[R package version 2.8.0].
18. Carlson M: hgu133a.db: Affymetrix Human Genome U133 Set annotation data (chip hgu133a). [R package version
2.8.0].
19. Dunning M, Lynch A, Eldridge M: illuminaHumanv3.db: Illumina HumanHT12v3 annotation data (chip illumi-
naHumanv3). [R package version 1.16.0].
20. Dunning M, Lynch A, Eldridge M: illuminaHumanv4.db: Illumina HumanHT12v4 annotation data (chip illumi-
naHumanv4). [R package version 1.16.0].
21. Benjamini Y, Yekutieli D:The control of the false discovery rate in multiple testing under dependency.
Ann. Statist. 2001, 29:1165–1188.
22. Expression Project for Oncology (expO)[http://www.intgen.org/research-services/biobanking-experience/expo/].
13
23. Chen L, Wang S, Zhou Y, Wu X, et al.: Identification of early growth response protein 1 (EGR-1) as
a novel target for JUN-induced apoptosis in multiple myeloma. Blood 2010, 115(1)::61–70.
24. de Jonge HJ, Valk PJ, Veeger NJ, ter Elst A, et al.: High VEGFC expression is associated with unique
gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid
leukemia. Blood 2010, 116(10):1747–54.
25. Roth R:Human body index - transcriptional profiling. Gene Expression Omnibus (GEO) NCBI2007:Series
GSE7307.
26. Haferlach T, Kohlmann A, Wieczorek L, Basso G, et al.: Clinical utility of microarray-based gene ex-
pression profiling in the diagnosis and subclassification of leukemia: report from the International
Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010, 28(15):2529–37.
27. Mills KI, Kohlmann A, Williams PM, Wieczorek L, et al.: Microarray-based classifiers and prognosis
models identify subgroups with distinct clinical outcomes and high risk of AML transformation of
myelodysplastic syndrome. Blood 2009, 114(5):1063–72.
28. Fehrmann RS, Jansen RC, Veldink JH, Westra HJ, et al.: Trans-eQTLs reveal that independent genetic
variants associated with a complex phenotype converge on intermediate genes, with a major role
for the HLA. PLoS Genet 2011, 7(8):e1002197.
29. Popovici V, Chen W, Gallas BG, Hatzis C, et al.: Effect of training-sample size and classification difficulty
on the accuracy of genomic predictors. Breast Cancer Res 2010, 12(1):R5.
30. Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, et al.: Addition of rituximab to chemotherapy overcomes
the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol
2013, 66(11):956–61.
31. Westra HJ, Peters MJ, Esko T, Yaghootkar H, et al.: Systematic identification of trans eQTLs as putative
drivers of known disease associations. Nat Genet 2013, 45(10):1238–43.
32. Barretina J, Caponigro G, Stransky N, Venkatesan K, et al.: The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature 2012, 483(7391):603–7.
33. Hernandez DG, Nalls MA, Moore M, Chong S, et al.: Integration of GWAS SNPs and tissue specific
expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis 2012,
47(1):20–8.
34. Mayerle J, den Hoed CM, Schurmann C, Stolk L, et al.: Identification of genetic loci associated with
Helicobacter pylori serologic status. JAMA 2013, 309(18):1912–20.
35. Xiao W, Mindrinos MN, Seok J, Cuschieri J, et al.: A genomic storm in critically injured humans. J Exp
Med 2011, 208(13):2581–90.
36. Seok J, Warren HS, Cuenca AG, Mindrinos MN, et al.: Genomic responses in mouse models poorly mimic
human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110(9):3507–12.
37. Marisa L, de Reynie`s A, Duval A, Selves J, et al.: Gene expression classification of colon can-
cer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013,
10(5):e1001453.
38. Wood AR, Hernandez DG, Nalls MA, Yaghootkar H, et al.: Allelic heterogeneity and more detailed
analyses of known loci explain additional phenotypic variation and reveal complex patterns of
association. Hum Mol Genet 2011, 20(20):4082–92.
39. Esko T, Metspalu A:Gene Expression profiling in healthy population samples. Gene Expression Omnibus
(GEO) NCBI2013:Series GSE48348.
40. Hollingshead MG, Stockwin LH, Alcoser SY, Newton DL, et al.: Microarray analysis of xenograft models
in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI).
Gene Expression Omnibus (GEO) NCBI2013:Series GSE48433.
41. Obermoser G, Presnell S, Domico K, Xu H, et al.: Systems scale interactive exploration reveals quan-
titative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity
2013, 38(4):831–44.
42. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E: A Cross-Study Comparison of Gene Ex-
pression Studies for the Molecular Classification of Lung Cancer. Clin Cancer Res 2004.
14
43. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, et al.: identification of genes with abnormal expression
changes in acute myeloid leukemia. Genes Chromosomes Cancer 2008, 47:8–20.
44. Zakaria Z, et al.: Identification of Estrogen-Related Genes in Breast Cancer: The Malaysian Context.
The Open Breast Cancer Journal 2010, 2:16–24.
45. Ma CX, Ellis MJ: The Cancer Genome Atlas: Clinical Applications for Breast Cancer. Oncology 2013,
27(12):1263–9.
46. Beljan PR, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M: IMP3 can predict aggressive
behaviour of lung adenocarcinoma. Diagn Pathol. 2012, 7:165.
47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL,
Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for
interpreting genome-wide expression profiles. PNAS 2005, 102:15545–15550.
48. Mosca E, Alfieri R, Merelli I, Viti F, Calabria A, Milanesi L: A multilevel data integration resource for
breast cancer study. BMC Syst Biol. 2010, 4:76.
49. Marchitti S, Orlicky D, Brocker C, Vasiliou V: Aldehyde Dehydrogenase 3B1 (ALDH3B1): Immunohis-
tochemical Tissue Distribution and Cellular-specific Localization in Normal and Cancerous Human
Tissues. J Histochem Cytochem 2010, 58(9):765–783.
50. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS: A census of overexpressed human cancer
genes. Nature Reviews Cancer 2010, 10:59–64.
51. Gurevich RM, Aplan PD, Humphries RK: NUP98-Topoisomerase I acute myeloid leukemia-associated
fusion gene has potent leukemogenic activities independent of an engineered catalytic site muta-
tion. Blood 2004, 104:1127–1136.
52. Ha¨rdle WK, Simar L: Applied Multivariate Statistical Analysis. Springer, New York 2012.
15
